vs
Journey Medical Corp（DERM）与Finward Bancorp（FNWD）财务数据对比。点击上方公司名可切换其他公司
Finward Bancorp的季度营收约是Journey Medical Corp的1.0倍（$16.5M vs $16.1M），Finward Bancorp净利率更高（12.0% vs -7.8%，领先19.8%），Journey Medical Corp同比增速更快（27.3% vs 1.1%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs -19.1%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
DERM vs FNWD — 直观对比
营收规模更大
FNWD
是对方的1.0倍
$16.1M
营收增速更快
DERM
高出26.2%
1.1%
净利率更高
FNWD
高出19.8%
-7.8%
两年增速更快
DERM
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $16.5M |
| 净利润 | $-1.2M | $2.0M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | 11.0% |
| 净利率 | -7.8% | 12.0% |
| 营收同比 | 27.3% | 1.1% |
| 净利润同比 | -182.0% | -5.6% |
| 每股收益（稀释后） | $-0.04 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMFNWD
| Q4 25 | $16.1M | $16.5M | ||
| Q3 25 | $17.0M | $17.4M | ||
| Q2 25 | $15.0M | $16.6M | ||
| Q1 25 | $13.1M | $15.5M | ||
| Q4 24 | $12.6M | $16.3M | ||
| Q3 24 | $14.6M | $14.9M | ||
| Q2 24 | $14.9M | $14.6M | ||
| Q1 24 | $13.0M | $25.3M |
净利润DERMFNWD
| Q4 25 | $-1.2M | $2.0M | ||
| Q3 25 | $-2.3M | $3.5M | ||
| Q2 25 | $-3.8M | $2.2M | ||
| Q1 25 | $-4.1M | $455.0K | ||
| Q4 24 | $1.5M | $2.1M | ||
| Q3 24 | $-2.4M | $606.0K | ||
| Q2 24 | $-3.4M | $143.0K | ||
| Q1 24 | $-10.4M | $9.3M |
毛利率DERMFNWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMFNWD
| Q4 25 | -2.8% | 11.0% | ||
| Q3 25 | -9.0% | 20.5% | ||
| Q2 25 | -19.2% | 12.7% | ||
| Q1 25 | -25.3% | 4.0% | ||
| Q4 24 | 17.7% | 16.3% | ||
| Q3 24 | -19.8% | 2.7% | ||
| Q2 24 | -19.7% | 0.9% | ||
| Q1 24 | -77.4% | 40.6% |
净利率DERMFNWD
| Q4 25 | -7.8% | 12.0% | ||
| Q3 25 | -13.6% | 20.1% | ||
| Q2 25 | -25.3% | 12.9% | ||
| Q1 25 | -31.0% | 2.9% | ||
| Q4 24 | 12.1% | 12.9% | ||
| Q3 24 | -16.3% | 4.1% | ||
| Q2 24 | -22.6% | 1.0% | ||
| Q1 24 | -80.1% | 36.7% |
每股收益（稀释后）DERMFNWD
| Q4 25 | $-0.04 | $0.46 | ||
| Q3 25 | $-0.09 | $0.81 | ||
| Q2 25 | $-0.16 | $0.50 | ||
| Q1 25 | $-0.18 | $0.11 | ||
| Q4 24 | $0.10 | $0.50 | ||
| Q3 24 | $-0.12 | $0.14 | ||
| Q2 24 | $-0.17 | $0.03 | ||
| Q1 24 | $-0.53 | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | — |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $174.7M |
| 总资产 | $94.6M | $2.0B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMFNWD
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
总债务DERMFNWD
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMFNWD
| Q4 25 | $31.9M | $174.7M | ||
| Q3 25 | $25.9M | $165.5M | ||
| Q2 25 | $19.2M | $154.3M | ||
| Q1 25 | $21.5M | $151.8M | ||
| Q4 24 | $20.1M | $151.4M | ||
| Q3 24 | $10.9M | $159.6M | ||
| Q2 24 | $11.3M | $148.6M | ||
| Q1 24 | $13.0M | $151.6M |
总资产DERMFNWD
| Q4 25 | $94.6M | $2.0B | ||
| Q3 25 | $85.2M | $2.1B | ||
| Q2 25 | $81.2M | $2.1B | ||
| Q1 25 | $85.0M | $2.0B | ||
| Q4 24 | $80.2M | $2.1B | ||
| Q3 24 | $64.0M | $2.1B | ||
| Q2 24 | $65.2M | $2.1B | ||
| Q1 24 | $66.6M | $2.1B |
负债/权益比DERMFNWD
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $9.0M |
| 自由现金流率自由现金流/营收 | — | 54.8% |
| 资本支出强度资本支出/营收 | — | 5.2% |
| 现金转化率经营现金流/净利润 | — | 4.99× |
| 过去12个月自由现金流最近4个季度 | — | $10.6M |
8季度趋势，按日历期对齐
经营现金流DERMFNWD
| Q4 25 | $-6.3M | $9.9M | ||
| Q3 25 | $-2.4M | $1.2M | ||
| Q2 25 | $-942.0K | $4.8M | ||
| Q1 25 | $-2.8M | $-3.8M | ||
| Q4 24 | $2.2M | $9.8M | ||
| Q3 24 | $-1.2M | $-3.7M | ||
| Q2 24 | $-5.2M | $2.8M | ||
| Q1 24 | $-5.0M | $-25.0K |
自由现金流DERMFNWD
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | — | $-4.2M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $-736.0K |
自由现金流率DERMFNWD
| Q4 25 | — | 54.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 27.0% | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | — | 41.2% | ||
| Q3 24 | — | -28.5% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | -2.9% |
资本支出强度DERMFNWD
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 18.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 11.2% | ||
| Q1 24 | — | 2.8% |
现金转化率DERMFNWD
| Q4 25 | — | 4.99× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | -8.37× | ||
| Q4 24 | 1.46× | 4.66× | ||
| Q3 24 | — | -6.15× | ||
| Q2 24 | — | 19.23× | ||
| Q1 24 | — | -0.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FNWD
暂无分部数据
